This company develops microfluidic automation systems to standardize and scale in vitro fertilization (IVF) laboratory workflows. Their technology reduces manual variability in embryology steps, aiming for more predictable laboratory performance. The OvaReady system specifically automates oocyte preparation to produce consistent, denuded oocytes suitable for clinical procedures.
Funding
$8.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
In vitro fertilization (IVF) procedures are often labor-intensive and costly, limiting accessibility for many infertility patients. The manual nature of these processes can also introduce variability, impacting the reliability and success rates of IVF treatments.
Solution
AutoIVF is developing high-throughput microfluidic technologies to automate key steps within the IVF process, reducing costs and improving treatment reliability. By automating these central procedures, AutoIVF aims to make IVF more accessible to a broader range of patients. Their platform targets specific components of the IVF procedure to streamline workflows and minimize manual intervention.
Target Audience
The primary target audience includes fertility clinics, IVF centers, and hospitals seeking to improve efficiency, reduce costs, and enhance the reliability of their IVF procedures.
Features
- Microfluidic devices for automated sperm selection and handling
- Integrated quality control and monitoring systems
- High-throughput processing capabilities for increased efficiency
- Reduced risk of human error through automation